Please assess the completion status of the following clinical trial:

Trial Title: Alphanate in Immune Tolerance Induction Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has a documented diagnosis of severe congenital hemophilia A with FVIII:C \<1% of normal.~* The subject is a male \<12 years (and at least 2 years of age if in India) at the Baseline Visit.~* The subject's documented historical peak inhibitor titer is ≥5 BU and ≤200 BU.~* The subject has an inhibitor titer \>0.6 BU and \<10 BU at Screening.~* The subject has had a delay ≤24 months from the date of diagnosis of the inhibitor to the start of the subject's ITI treatment.~Exclusion Criteria:~* The subject has acquired factor VIII (FVIII) deficiency.~* The subject has previously received ITI treatment.~* The subject has a recent (within 1 month) history of central line infection at the time of Screening.~* The subject has a high risk of cardiovascular, cerebrovascular, or thromboembolic event as judged by the investigator.~* The subject is currently undergoing treatment with immunosuppressive drugs (eg, systemic corticosteroids), azathioprine, cyclophosphamide, high dose immunoglobulin, interferon, or the use of a protein A column or plasmapheresis and is unwilling to discontinue these treatments starting at the screening visit.~* The subject has a known infection with human immunodeficiency virus (HIV) or has clinical signs and symptoms consistent with current HIV infection.~* The subject has a known previous infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) or has clinical signs and symptoms consistent with current HBV or HCV infection.~* The subject has significant proteinuria, has a history of acute renal failure or severe renal impairment (blood urea nitrogen or creatinine \>2 times the upper limit of normal), or is receiving dialysis at Screening.~* The subject has a value of aspartate transaminase or alanine aminotransferase \>2 times the upper limit of normal at Screening.~* The subject has clinical evidence of any significant acute or chronic disease that, in the opinion of the investigator, may interfere with successful completion of the trial or place the subject at undue medical risk.~* The subject has a history of anaphylaxis or severe systemic reaction to any plasma derived or other blood products.

- Gender: MALE
- Minimum Age: None
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Alphanate (Type: EXPERIMENTAL): Participants were to receive alphanate 100 International Units (IU/kg/day) for up to 33 months in Immune tolerance induction (ITI) Treatment Phase. The dose could be increased up to 200 IU/kg/day based on Investigator's discretion. Following ITI Treatment Phase, participants were to enter the Prophylactic Phase where alphanate dose was to be tapered down in a step wise manner to reach a final prophylactic dose of 50 IU/kg every other day or 3 times per week, at the investigator's discretion.

Based on this trial design, predict the completion outcome and termination type (if applicable).